Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3B | Q9UBC3 | 9/20 | 1.00 |
| ▸ | DNMT1 | P26358 | 8/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 11/20 | 0.78 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.70 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.65 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17309766 | 1.00 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1CARM1 | |
| SCHEMBL14174643 | 0.96 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1CARM1 | |
| SCHEMBL30225688 | 0.96 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1CARM1 | |
| SCHEMBL5055207 | 0.96 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1CARM1 | |
| SCHEMBL17309760 | 0.96 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1CARM1 | |
| SCHEMBL17309762 | 0.91 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1CARM1 | |
| SCHEMBL14174713 | 0.91 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1CARM1 | |
| SCHEMBL5052474 | 0.89 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1 | |
| SCHEMBL17309755 | 0.89 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1 | |
| SCHEMBL30225680 | 0.89 | DNMT3B (1.00) | DNMT3BDNMT1DOT1LPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952182-B1 | Compounds and methods for increasing the immune response to papillomavirus | UNIV HEIDELBERG (DE) | 2022-11-23 | — | — | EP | claimed |
| US-20250161351-A1 | CANCER TREATMENT BY ARSENIC TRIOXIDE COMBINATION THERAPY | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-22 | — | — | US | disclosed |